Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach

Vicagrel, a novel acetate derivative of clopidogrel, exhibits a favorable safety profile and excellent antiplatelet activity. Studies aim at identifying genetic and non-genetic factors affecting vicagrel metabolic enzymes Cytochrome P450 2C19 (CYP2C19), Carboxylesterase (CES) 1 and 2 (CES1 and CES2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuaibing, Wang, Ziteng, Tian, Xin, Cai, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793822/
https://www.ncbi.nlm.nih.gov/pubmed/33424602
http://dx.doi.org/10.3389/fphar.2020.591854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793822/
https://www.ncbi.nlm.nih.gov/pubmed/33424602
http://dx.doi.org/10.3389/fphar.2020.591854

Ejemplares similares